Pfizer has reported a strong second quarter under Jewish CEO Albert Bourla, bringing in nearly $15 billion in sales as demand rose for several of its biggest medicines. The results came in above Wall Street expectations and gave the company fresh momentum after years of falling COVID-related revenue.
By Levy Mayer
